Hospital De Basurto

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Metastatic breast cancer3 trials
• Atrial fibrillation1 trial
• Bladder cancer1 trial
• Childhood cancers1 trial
• Coronary artery disease1 trial
• Diabetic eye disease1 trial
• Gastric and oesophageal cancer1 trial
• Idiopathic pulmonary fibrosis1 trial
• Immune thrombocytopenia (ITP)1 trial
• Liver and biliary tract cancer1 trial
• Macular degeneration1 trial
• and 3 more

Phase

• Phase 310 trials
• Phase 22 trials
• Phase 41 trial

Status

• Completed8 trials
• Active, not recruiting7 trials
• Recruiting3 trials
• Terminated2 trials

Lead sponsor

• Hoffmann-La Roche6 trials
• Fundación GECP3 trials
• BeiGene1 trial
• Boehringer Ingelheim1 trial
• Boston Scientific Corporation1 trial
• and 8 more

Running trials

• Active, not recruiting

  A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation

  NCT06808217· Boston Scientific Corporation· Source

• Recruiting

  Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

  NCT06634199· Fundación GECP· Source

  Contact: Mª Angeles Sala González, MD

• Recruiting

  RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia

  NCT06919341· Fundación Española de Hematología y Hemoterapía· Source

  Contact: Laura Hernández Vázquez

• Active, not recruiting

  A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

  NCT05776472· Swedish Orphan Biovitrum· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

  NCT05382052· Fundación GECP· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

  NCT04434092· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

  NCT04432584· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

  NCT03595592· Phase 3· Fondazione Michelangelo· Source

• Recruiting

  Thoracic Tumours Register

  NCT02941458· Spanish Lung Cancer Group· Source

  Contact: Mª Ángeles Sala, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma

  NCT05005429· Phase 2· Fundación GECP· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Terminated

  A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

  NCT04732286· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

  NCT04148911· Phase 3· Hoffmann-La Roche· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Completed

  TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

  NCT03596385· Phase 4· Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

  NCT02448420· Phase 2· SOLTI Breast Cancer Research Group· Source